|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
|
WO1997018833A1
(en)
*
|
1995-11-22 |
1997-05-29 |
Amgen Inc. |
Methods of increasing lean tissue mass using ob protein compositions
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
|
AU770897B2
(en)
*
|
1996-12-20 |
2004-03-04 |
Amgen, Inc. |
OB fusion protein compositions and methods
|
|
WO1998028427A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Amgen Inc. |
Ob fusion protein compositions and methods
|
|
CN1202862C
(zh)
*
|
1997-04-17 |
2005-05-25 |
安姆根有限公司 |
包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
|
|
AU2002300605B8
(en)
*
|
1997-04-17 |
2006-02-09 |
Amgen Inc. |
Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
|
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
|
EP1489100B1
(en)
|
1997-12-08 |
2016-06-15 |
Merck Patent GmbH |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
JP4380067B2
(ja)
|
1998-04-23 |
2009-12-09 |
味の素株式会社 |
抗血栓活性物質及びグリコカリシンの検出法
|
|
US6492138B1
(en)
|
1998-05-21 |
2002-12-10 |
Amgen Canada Inc. |
Polynucleotides encoding a novel SHC-binding protein
|
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
DE60129695T2
(de)
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
US6962903B2
(en)
|
2001-02-21 |
2005-11-08 |
Alavita, Inc. |
Modified annexin proteins and methods for preventing thrombosis
|
|
US7645739B2
(en)
|
2001-02-21 |
2010-01-12 |
Alavita Pharmaceuticals, Inc. |
Modified annexin compositions and methods of using same
|
|
US7635676B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaccuticals, Inc. |
Modified annexin proteins and methods for their use in organ transplantation
|
|
AU2002248571B2
(en)
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
PT1383785E
(pt)
|
2001-05-03 |
2011-06-28 |
Merck Patent Gmbh |
Anticorpo recombinante específico de tumores e utilização deste
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
CN100432105C
(zh)
|
2002-12-17 |
2008-11-12 |
默克专利有限公司 |
与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
|
|
CA2509755A1
(en)
|
2002-12-27 |
2004-07-22 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
ATE555133T1
(de)
*
|
2003-11-13 |
2012-05-15 |
Hanmi Holdings Co Ltd |
Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
|
|
CA2551915C
(en)
|
2003-12-30 |
2015-06-23 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Il-7 fusion proteins
|
|
JP2008504008A
(ja)
|
2003-12-31 |
2008-02-14 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
|
|
AU2005203962C1
(en)
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
KR100639397B1
(ko)
*
|
2004-03-18 |
2006-10-26 |
(주)에스제이바이오메드 |
항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
|
|
CN101072793B
(zh)
|
2004-12-09 |
2012-06-20 |
默克专利有限公司 |
具有降低的免疫原性的il-7变体
|
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
US8716220B2
(en)
|
2005-09-07 |
2014-05-06 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
|
|
US8642543B2
(en)
|
2005-09-07 |
2014-02-04 |
Neurotez, Inc. |
Methods for treating progressive cognitive disorders related to neurofibrillary tangles
|
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
|
EP2421896A1
(en)
|
2009-04-22 |
2012-02-29 |
Merck Patent GmbH |
Antibody fusion proteins with modified fcrn binding sites
|
|
CN104147596A
(zh)
*
|
2013-05-14 |
2014-11-19 |
李荣秀 |
生物药非共价结合聚合物延长治疗浓度的方法及用途
|
|
CN104524568B
(zh)
*
|
2015-01-08 |
2018-04-20 |
中国人民解放军第二军医大学 |
一种治疗肥胖症的药物组合物及其应用
|